In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate
Open Access
- 2 May 2002
- journal article
- Published by Springer Nature in BMC Pharmacology
- Vol. 2 (1) , 11
Abstract
Leishmaniasis is a common parasitic disease in Southern Europe, caused by Leishmania infantum. The failures of current treatment with pentavalent antimonials are partially attributable to the emergence of antimony-resistant Leishmania strains. This study analyses the in vitro susceptibility to pentavalent antimony of intracellular amastigotes from a range of L. infantum strains, derived from the same infected animal, during in vitro and in vivo passages and after host treatment with meglumine antimoniate. SbV-IC50 values for strains from two distinct isolates from the same host and one stock after two years of culture in NNN medium and posterior passage to hamster were similar (5.0 +/- 0.2; 4.9 +/- 0.2 and 4.4 +/- 0.1 mgSbV/L, respectively). In contrast, a significant difference (P < 0.01, t test) was observed between the mean SbV-IC50 values in the stocks obtained before and after treatment of hosts with meglumine antimoniate (4.7 +/- 0.4 mgSbV/L vs. 7.7 +/- 1.5 mgSbV/L). Drug-resistance after drug pressure in experimentally infected dogs increased over repeated drug administration (6.4 +/- 0.5 mgSbV/L after first treatment vs. 8.6 +/- 1.4 mgSbV/L after the second) (P < 0.01, t test). These results confirm previous observations on strains from Leishmania/HIV co-infected patients and indicate the effect of the increasing use of antimony derivatives for treatment of canine leishmaniasis in endemic areas on the emergence of Leishmania antimony-resistant strains.Keywords
This publication has 19 references indexed in Scilit:
- Virulence ofLeishmania infantumIs Expressed as a Clonal and Dominant Phenotype in Experimental InfectionsInfection and Immunity, 2001
- The increase in risk factors for leishmaniasis worldwideTransactions of the Royal Society of Tropical Medicine and Hygiene, 2001
- Long term improvement in the treatment of canine leishmaniosis using an antimony liposomal formulationVeterinary Parasitology, 2001
- In vitro susceptibility of Leishmania infantum to meglumine antimoniate in isolates from repeated leishmaniasis episodes in HIV-coinfected patientsJournal of Antimicrobial Chemotherapy, 2001
- Leishmania infantum: Stage-Specific Activity of Pentavalent Antimony Related with the Assay ConditionsExperimental Parasitology, 2000
- Evidence that the High Incidence of Treatment Failures in Indian Kala‐Azar Is Due to the Emergence of Antimony‐Resistant Strains ofLeishmania donovaniThe Journal of Infectious Diseases, 1999
- Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniateVeterinary Parasitology, 1999
- Epidemiology of canine leishmaniosis in Catalonia (Spain)Veterinary Parasitology, 1999
- LeishmaniasisClinics in Dermatology, 1996
- Leishmania spp.: Development of pentostam-resistant clones in vitro by discontinuous drug exposureExperimental Parasitology, 1989